"The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa&rsqu"...
Xigris (drotrecogin alfa) is administered in the intensive care unit, and in this setting, patients may be unresponsive or may have difficulty comprehending counseling information.
Patients and patients' caregivers should be informed by their healthcare provider of the potential benefits and risks associated with Xigris (drotrecogin alfa) , including the most common side effect, bleeding. Patients with clinical conditions likely to increase the risk of bleeding should be carefully evaluated and anticipated benefits weighed against potential risks associated with Xigris therapy [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS].
Last reviewed on RxList: 10/31/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Xigris Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.